It would also be possible to pretreat pulsed DCs with mRNAs (encoding TAAs) or siRNAs (targeting PD-L1 and PD-L2) prior to their administration in order to increase their ability to present tumor antigens to T-cells and to mitigate the impact of the TME on DCs in melanoma settings [169,170,171]. The gene discussed is CD274; the disease is melanoma.